{"id":"optive","safety":{"commonSideEffects":[{"rate":null,"effect":"Transient blurred vision"},{"rate":null,"effect":"Eye irritation"},{"rate":null,"effect":"Mild ocular discomfort"}]},"_chembl":null,"_dailymed":{"setId":"326cb5d6-c784-404f-9a13-6d69262dda6e","title":"REFRESH OPTIVE MEGA-3 PF (CARBOXYMETHYLCELLULOSE SODIUM, GLYCERIN, POLYSORBATE 80) SOLUTION/ DROPS [ALLERGAN, INC.]"},"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Optive combines multiple lubricating agents including carboxymethylcellulose and glycerin to provide sustained moisture and protection to the cornea and conjunctiva. The formulation mimics natural tears and helps restore the tear film, reducing irritation, grittiness, and discomfort associated with dry eye syndrome. It also contains electrolytes to maintain osmotic balance and support ocular surface health.","oneSentence":"Optive is an artificial tear solution that lubricates and protects the ocular surface to relieve symptoms of dry eye disease.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-27T23:58:32.393Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Dry eye disease / Keratoconjunctivitis sicca"}]},"trialDetails":[{"nctId":"NCT07284381","phase":"PHASE3","title":"A Clinical Study to Evaluate the Effect and Side Effect of a New Artificial Tear Formulation (ABBV-444) Compared to Refresh Optive Unit Dose in Adult Participants With Dry Eye Disease","status":"RECRUITING","sponsor":"AbbVie","startDate":"2025-12-15","conditions":"Dry Eye Disease","enrollment":250},{"nctId":"NCT06375343","phase":"PHASE1","title":"Study to Evaluating PRO-240 Ophthalmic Solution Compared to Optive®","status":"NOT_YET_RECRUITING","sponsor":"Laboratorios Sophia S.A de C.V.","startDate":"2026-01-30","conditions":"Dry Eye Disease, Dry Eye Sensation, Ocular Surface Disease","enrollment":32},{"nctId":"NCT06221345","phase":"PHASE4","title":"Hyaluronic Acid-containing Artificial Tears in Post-cataract Surgery Dry Eye Disease","status":"COMPLETED","sponsor":"Chang Gung Memorial Hospital","startDate":"2021-12-07","conditions":"Dry Eye Disease, Cataract","enrollment":70},{"nctId":"NCT00610480","phase":"NA","title":"Tear Film Stability After Instillation of Over-the-Counter (OTC) Artificial Drops","status":"COMPLETED","sponsor":"University of Texas Southwestern Medical Center","startDate":"2007-11","conditions":"Dry Eye Disease","enrollment":20},{"nctId":"NCT03208673","phase":"NA","title":"Optive Brand For Day And Night Dry Eye Management","status":"COMPLETED","sponsor":"Allergan","startDate":"2017-07-03","conditions":"Dry Eye","enrollment":35},{"nctId":"NCT02776670","phase":"NA","title":"Clinical Outcomes Following Treatment With SYSTANE® BALANCE","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2016-07-29","conditions":"Dry Eye","enrollment":308},{"nctId":"NCT02117687","phase":"PHASE4","title":"A Safety and Efficacy Study of OPTIVE FUSION™ With VISMED® Multi for the Management of Dry Eye","status":"COMPLETED","sponsor":"Allergan","startDate":"2014-05-14","conditions":"Dry Eye Syndromes, Keratoconjunctivitis Sicca","enrollment":80},{"nctId":"NCT02121847","phase":"PHASE4","title":"Investigation of Maintaining Visual Performance Achieved With Cyclosporine Therapy","status":"COMPLETED","sponsor":"Allergan","startDate":"2014-04-03","conditions":"Dry Eye Syndromes","enrollment":40},{"nctId":"NCT02280473","phase":"PHASE3","title":"A Safety and Efficacy Study of Refresh Optive® Gel Drops in Patients With Dry Eye Disease","status":"COMPLETED","sponsor":"Allergan","startDate":"2014-11-13","conditions":"Dry Eye Syndromes","enrollment":188},{"nctId":"NCT01459588","phase":"PHASE3","title":"Safety, Efficacy, and Acceptability Study of an Eye Drop Formulation in Subjects With Dry Eye Disease","status":"COMPLETED","sponsor":"Allergan","startDate":"2011-10-01","conditions":"Dry Eye Syndromes","enrollment":315},{"nctId":"NCT02553772","phase":"PHASE3","title":"A Safety and Efficacy Study of a New Eye Drop Formulation in Patients With Dry Eye Disease.","status":"COMPLETED","sponsor":"Allergan","startDate":"2016-01-06","conditions":"Dry Eye Syndromes","enrollment":242},{"nctId":"NCT03140111","phase":"NA","title":"LAMELLEYE for the Treatment of Dry Eye Symptoms in pSS Patients","status":"UNKNOWN","sponsor":"NHS Greater Glasgow and Clyde","startDate":"2017-10-16","conditions":"Dry Eye Syndromes, Primary Sjögren Syndrome","enrollment":12},{"nctId":"NCT03052140","phase":"NA","title":"Lamelleye vs Comparator for the Treatment of Dry Eye Disease","status":"COMPLETED","sponsor":"Glasgow Caledonian University","startDate":"2017-02-21","conditions":"Dry Eye Syndromes","enrollment":31},{"nctId":"NCT02617095","phase":"NA","title":"Comparison of the Efficacy and Safety of T2762 Versus Optive® in the Treatment of Moderate to Severe Dry Eye Syndrome","status":"TERMINATED","sponsor":"Laboratoires Thea","startDate":"2015-02","conditions":"Dry Eye Syndrome","enrollment":64},{"nctId":"NCT01741987","phase":"NA","title":"Osmoprotective Containing Lubricants in Dysfunctional Tear Syndrome and Post Refractive Surgery Patients","status":"COMPLETED","sponsor":"Federal University of São Paulo","startDate":"2008-10","conditions":"Dry Eye, Ametropia","enrollment":100},{"nctId":"NCT01863368","phase":"NA","title":"Clinical Evaluation of Systane® ULTRA Compared to OPTIVE® in Ocular Surface Staining","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2013-09","conditions":"Dry Eye Syndrome","enrollment":105},{"nctId":"NCT00691197","phase":"PHASE2, PHASE3","title":"Safety and Acceptability of Using a Rewetting Drop With Contact Lens Wear","status":"COMPLETED","sponsor":"Allergan","startDate":"2008-03","conditions":"Ametropia","enrollment":246},{"nctId":"NCT01799863","phase":"PHASE2, PHASE3","title":"Artificial Tears Versus Preservative Free Ketorolac Trometamol 0.45% for Acute Viral Conjunctivitis","status":"COMPLETED","sponsor":"Fundação Altino Ventura","startDate":"2012-06","conditions":"Conjunctivitis, Viral","enrollment":50},{"nctId":"NCT01711424","phase":"","title":"An Observational Study of OPTIVE PLUS® for the Treatment of Dry Eye Disease","status":"COMPLETED","sponsor":"Allergan","startDate":"2012-09","conditions":"Dry Eye Syndromes","enrollment":1209},{"nctId":"NCT00761202","phase":"PHASE4","title":"Performance and Acceptance of Optive Versus Hylocomod Eyedrops in Patients With Dry Eye Symptoms","status":"COMPLETED","sponsor":"Allergan","startDate":"2007-08","conditions":"Dry Eye Syndromes","enrollment":50},{"nctId":"NCT01417013","phase":"NA","title":"Comparative Efficacy of SYSTANE® ULTRA vs Optive™ in Improving Tear Film Break-up Time","status":"WITHDRAWN","sponsor":"Alcon Research","startDate":"2011-07","conditions":"Dry Eye","enrollment":""},{"nctId":"NCT00756678","phase":"PHASE4","title":"Efficacy and Acceptability of Two Lubricant Eye Drops","status":"COMPLETED","sponsor":"Allergan","startDate":"2008-09","conditions":"Dry Eye Syndromes","enrollment":51},{"nctId":"NCT00938704","phase":"PHASE4","title":"Study to Compare the Efficacy and Safety of Two Non-Preserved Artificial Tears for the Treatment of Dry Eye Signs and Symptoms","status":"COMPLETED","sponsor":"Allergan","startDate":"2009-06","conditions":"Dry Eye Syndromes","enrollment":71},{"nctId":"NCT00987727","phase":"PHASE4","title":"Safety and Efficacy of Carboxymethylcellulose for Ocular Surface Integrity in Symptomatic Dry Eye","status":"COMPLETED","sponsor":"Allergan","startDate":"2009-11","conditions":"Dry Eye Syndromes, Keratoconjunctivitis Sicca","enrollment":82},{"nctId":"NCT00405457","phase":"PHASE4","title":"Efficacy and Safety of a New Multi-dose Lubricant Eye Drop Concomitant With Restasis® (Cyclosporine A) for the Treatment of Dry Eye Symptoms","status":"COMPLETED","sponsor":"Innovative Medical","startDate":"2006-11","conditions":"Dry Eye","enrollment":50},{"nctId":"NCT00893243","phase":"","title":"Efficacy Comparative Study Between Tears Again®, Opticol® and Optive®","status":"COMPLETED","sponsor":"Hospital de Sao Sebastiao","startDate":"","conditions":"Dry Eye Syndrome","enrollment":27}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":38,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Optive®","genericName":"Optive®","companyName":"Laboratorios Sophia S.A de C.V.","companyId":"laboratorios-sophia-s-a-de-c-v","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Optive is an artificial tear solution that lubricates and protects the ocular surface to relieve symptoms of dry eye disease. Used for Dry eye disease / Keratoconjunctivitis sicca.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}